Extracellular vesicles for the treatment of central nervous system diseases

被引:43
|
作者
Gratpain, Viridiane [1 ]
Mwema, Ariane [1 ,2 ]
Labrak, Yasmine [1 ,2 ]
Muccioli, Giulio G. [2 ]
van Pesch, Vincent [3 ,4 ]
des Rieux, Anne [1 ]
机构
[1] Catholic Univ Louvain, Louvain Drug Res Inst, Adv Drug Delivery & Biomat, UCLouvain, B-1200 Brussels, Belgium
[2] Catholic Univ Louvain, Louvain Drug Res Inst, Bioanal & Pharmacol Bioact Lipids, UCLouvain, B-1200 Brussels, Belgium
[3] Catholic Univ Louvain, Inst Neurosci, Neurochem Unit, UCLouvain, B-1200 Brussels, Belgium
[4] Clin Univ St Luc, B-1200 Brussels, Belgium
关键词
miRNA; Nose to brain; Glioblastoma; Neurodegeneration; Neuroinflammation; Surface modification; Nanocarriers; Drug Delivery; Multiple Sclerosis; BLOOD-BRAIN-BARRIER; MESENCHYMAL STROMAL CELLS; CONVECTION-ENHANCED DELIVERY; DRUG-DELIVERY; ALPHA-SYNUCLEIN; IN-VITRO; PARKINSONS-DISEASE; ENDOTHELIAL MICROPARTICLES; ALZHEIMER-DISEASE; MEDIATED TRANSFER;
D O I
10.1016/j.addr.2021.05.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The interest in extracellular vesicles (EVs) increased during the last decade. It is now established that these vesicles play a role in the pathogenesis of central nervous system diseases (CNS), which explains why they are studied as biomarkers in these pathologies. On the other hand, EVs can also present ther-apeutic properties, often similar to their parent cells, as observed with mesenchymal stem cell-derived EVs. They can then be used as therapeutics, alone or combined with a bioactive molecule, for the treat-ment of CNS diseases, as they can cross the blood-brain barrier more easily than synthetic nanomedici-nes and are less immunogenic. A few clinical trials are currently on-going but there are still challenges to overcome for further clinical translation such as the scale-up of the production, the lack of standardiza-tion for isolation and characterization methods and the low encapsulation efficiency. (c) 2021 Elsevier B.V. All rights reserved.
引用
下载
收藏
页码:535 / 552
页数:18
相关论文
共 50 条
  • [21] Delivery of Therapeutic Agents to the Central Nervous System and the Promise of Extracellular Vesicles
    Rene, Charlotte A.
    Parks, Robin J.
    PHARMACEUTICS, 2021, 13 (04)
  • [22] Enrichment of extracellular vesicles from tissues of the central nervous system by PROSPR
    Xavier Gallart-Palau
    Aida Serra
    Siu Kwan Sze
    Molecular Neurodegeneration, 11
  • [23] Targeted Drug Delivery to the Central Nervous System Using Extracellular Vesicles
    Zhou, Lina
    Kodidela, Sunitha
    Godse, Sandip
    Thomas-Gooch, Stacey
    Kumar, Asit
    Raji, Babatunde
    Zhi, Kaining
    Kochat, Harry
    Kumar, Santosh
    PHARMACEUTICALS, 2022, 15 (03)
  • [24] Enrichment of extracellular vesicles from tissues of the central nervous system by PROSPR
    Gallart-Palau, Xavier
    Serra, Aida
    Sze, Siu Kwan
    MOLECULAR NEURODEGENERATION, 2016, 11
  • [25] Extracellular particles: emerging insights into central nervous system diseases
    Shenyuan Chen
    Qinghua Bao
    Wenrong Xu
    Xiao Zhai
    Journal of Nanobiotechnology, 23 (1)
  • [26] Neutrophil extracellular traps in central nervous system (CNS) diseases
    Shao, Bo-Zong
    Jiang, Jing-Jing
    Zhao, Yi-Cheng
    Zheng, Xiao-Rui
    Xi, Na
    Zhao, Guan-Ren
    Huang, Xiao-Wu
    Wang, Shu-Ling
    PEERJ, 2024, 12
  • [27] Extracellular matrix degradation by metalloproteinases and central nervous system diseases
    Lukes, A
    Mun-Bryce, S
    Lukes, M
    Rosenberg, GA
    MOLECULAR NEUROBIOLOGY, 1999, 19 (03) : 267 - 284
  • [28] Extracellular proteases and their inhibitors in genetic diseases of the central nervous system
    Molinari, F
    Meskanaite, V
    Munnich, A
    Sonderegger, P
    Colleaux, L
    HUMAN MOLECULAR GENETICS, 2003, 12 : R195 - R200
  • [29] Extracellular matrix degradation by metalloproteinases and central nervous system diseases
    Anton Lukes
    Sheila Mun-Bryce
    Manuela Lukes
    Gary A. Rosenberg
    Molecular Neurobiology, 1999, 19 : 267 - 284
  • [30] Xenotransplantations in treatment of diseases of central nervous system
    Permyakov, NK
    Savelyev, SV
    ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 1998, 98 (02): : 59 - 61